Lava Therapeutics Nv Reports Results For The Quarter Ended In September: Earnings Summary

LAVA Therapeutics NV

16/11/2022 21:22

* LAVA Therapeutics NV  LVTX.OQ  reported quarterly adjusted
earnings of 4 cents​​ per share for the quarter ended in
September. The mean expectation of five analysts for the quarter
was for a loss of 14 cents per share.
    * Revenue rose 756.7% to €15.26 million from a year ago;
analysts
expected €10.20 million. 
    * LAVA Therapeutics NV's reported EPS for the quarter was 4
cents​.
    * The mean earnings estimate of analysts had risen by
about 73.6%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * LAVA Therapeutics NV shares had risen by 16.8% this
quarter and
lost 2.9% so far this year.
    * The company reported quarterly net income of €997
thousand.
    * Wall Street's median 12-month price target for LAVA
Therapeutics
NV is $20.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
16 at 09:22 p.m.  ​All figures in euros unless otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.14          0.04           Beat
 Jun. 30 2022      -0.59          -0.31          Beat
 Mar. 31 2022      -0.81          -0.41          Beat
 Dec. 31 2021      -0.36          -0.38          Missed